Ghrelin: the hunger hormone your stomach makes
A natural hormone released by the stomach that signals hunger to the brain and triggers growth hormone release; natural hormone, not a drug.
- Class
- Endogenous gut hormone / GHS-R1a natural ligand
- Status
- Not an approved therapeutic; endogenous hormone and pharmacological reference for the GHS-R1a pathway
- Best-supported effect
- Appetite stimulation and pituitary GH release — established as core human physiology (human observational/physiological evidence); exogenous therapeutic use limited to small human research studies (cancer cachexia, anorexia nervosa, functional GI disorders), not approved
- Main caveat
- Strong evidence applies to ghrelin's endogenous physiology, not to exogenous native ghrelin as a therapeutic. Approved development in this pathway has focused entirely on synthetic GHS-R1a agonists (anamorelin, macimorelin, GHRP series) — distinct compounds that must not be conflated with native ghrelin.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Ghrelin is a 28-amino-acid peptide hormone produced primarily by X/A-like cells of the gastric fundus. It is the body's principal circulating orexigenic — appetite-stimulating — signal and the natural endogenous ligand of the growth hormone secretagogue receptor GHS-R1a. Ghrelin circulates in two major forms: acyl-ghrelin, the biologically active form carrying an octanoyl group on Serine-3 installed post-translationally by ghrelin-O-acyltransferase (GOAT/MBOAT4), and des-acyl ghrelin, which lacks this modification and has distinct, still-contested biology. The raw sequence stored here — GSSFLSPEHQRVQQRKESKKPPAKLQPR — represents the unmodified 28-residue chain; the octanoyl group on Ser3 that confers full GHS-R1a agonist activity is absent from the stored sequence.
Ghrelin serves primarily as a pharmacological reference and biology anchor. It is the endogenous molecule that the entire class of synthetic growth hormone secretagogues — GHRP-2, GHRP-6, hexarelin, ipamorelin, MK-677 — was designed to mimic. Exogenous native ghrelin has been administered in controlled human research studies and small clinical trials investigating cancer cachexia, anorexia nervosa, and functional gastrointestinal disorders, but it has not been developed into an approved therapeutic for any indication. Commercial development of the ghrelin pathway has concentrated on synthetic agonists (anamorelin, relamorelin, macimorelin), not on native ghrelin itself.
History
Ghrelin's discovery resolved a long-standing mystery in receptor pharmacology. Synthetic growth hormone secretagogues — peptides like GHRP-6 that drove pituitary GH release through a pathway distinct from GHRH — had been developed since the 1980s. Their receptor was cloned by a Merck team in 1996 but remained an orphan; no endogenous ligand was known. In 1999 Masayasu Kojima and Kenji Kangawa, at the National Cardiovascular Center Research Institute in Japan, isolated a 28-amino-acid peptide from rat stomach that activated the orphan receptor with high potency and named it ghrelin — from the Proto-Indo-European root ghre- (to grow) — in recognition of its growth-hormone-releasing activity (Kojima et al., Nature 1999). Subsequent human studies established the pre-meal rise in circulating ghrelin and its post-meal suppression, confirmed its role in appetite initiation, and documented the dramatic fall in ghrelin levels after gastric bypass surgery. The critical octanoylation reaction was puzzling for nearly a decade until Yang and colleagues identified GOAT (ghrelin-O-acyltransferase, encoded by MBOAT4) in 2008 as the enzyme responsible, opening the door to GOAT inhibition as a potential obesity strategy. The endogenous counter-signal arrived in 2018, when Ge and colleagues identified LEAP2 as a GHS-R1a inverse agonist (Ge et al., Cell Metabolism 2018), shifting the field's understanding of receptor tone from a simple agonist-only model to a ratio-dependent one.
What it does
Ghrelin tells the brain that the body is ready to eat. Levels rise before meals, fall after feeding, and track changes in energy state — including the dramatic drop seen after gastric bypass surgery. At the pituitary, ghrelin is the endogenous trigger for pulsatile growth hormone release, which is why the entire GHRP class of synthetic peptides produces GH secretion. Beyond appetite and GH, ghrelin acts in mesolimbic reward circuits through GHS-R1a heterodimers with dopamine receptors, providing a molecular basis for its reported role in food-reward behavior beyond simple hunger. Des-acyl ghrelin — which predominates in circulation over the octanoylated form — does not bind GHS-R1a and is thought to have independent but incompletely characterized effects through an as-yet-unidentified receptor.
Evidence
- Human: Strong for ghrelin's endogenous physiology — pre-meal rise, appetite stimulation, pulsatile GH release, and the post-bariatric appetite suppression associated with ghrelin decline are established through published human observational and physiological studies. Exogenous native ghrelin has been administered in small research studies of cancer cachexia and anorexia nervosa, but no large Phase III trial of native ghrelin has been completed and no indication has been approved. Approved clinical evidence in this pathway derives from synthetic agonists: anamorelin for cancer cachexia (approved in Japan, 2020) and macimorelin for adult GH deficiency diagnosis (FDA-approved 2017); these are distinct compounds and their evidence does not transfer to native ghrelin.
- Animal: Extensive. GHS-R1a knockout, GOAT-knockout, and LEAP2-manipulation rodent models have mapped the ghrelin signaling axis, including food reward, GH pulsatility, adiposity induction, and stress-eating behaviors (Baldanzi et al., J Cell Biology 2002).
- In vitro: Strong for receptor pharmacology. GHS-R1a signaling, GOAT enzymology, allosteric modulation by membrane lipids (Damian et al., Nature Communications 2021), and cryo-EM structural characterization of GHS-R1a bound to ghrelin and to synthetic agonists are well-established in cell and biochemical systems.
Known effects
- Appetite stimulation — Core human physiology; orexigenic role established in published human studies
- Pulsatile GH release — Core human physiology; GHS-R1a activation in anterior pituitary somatotrophs
- Pre-meal rise / post-meal suppression — Established human observational evidence; the most consistent circadian biomarker in the hunger-satiety axis
- Post-bariatric appetite reduction — Human observational evidence; ghrelin levels fall markedly after gastric bypass, contributing to appetite loss
- Cardioprotection (des-acyl ghrelin) — Preclinical; Baldanzi and colleagues showed both acyl and des-acyl ghrelin inhibit cardiomyocyte and endothelial cell death through ERK1/2 and PI3-kinase/AKT (Baldanzi et al., J Cell Biology 2002)
- Food reward and mesolimbic signaling — Mechanistic / preclinical; GHS-R1a heterodimers with dopamine D1/D2 receptors are characterized at the molecular level
- Ghrelin-receptor antagonism as obesity treatment — Not established despite multiple programs; consistently underperformed clinical expectations
Safety signals
Adverse events reported in human research infusion studies include flushing, headache, transient nausea, increased hunger and caloric intake (expected pharmacology), a transient GH spike with associated fluid retention, and mild cortisol and prolactin elevation. These observations come from controlled research settings using IV administration, not from approved therapeutic use.
Membrane lipid composition modulates GHS-R1a signaling efficacy and selectivity — PIP2 shifts the receptor toward an active state favoring G protein coupling, while GM3 exerts distinct modulatory effects — suggesting that pharmacological context can substantially alter receptor behavior (Damian et al., Nature Communications 2021).
A class-level concern for sustained GHS-R1a agonism is chronic GH-axis activation with associated insulin resistance and fluid retention; this is more relevant to long-acting synthetic analogs than to native ghrelin's sub-30-minute plasma half-life for the acyl form. Long-term consequences of chronic GHS-R1a agonism in healthy populations — cancer risk, cardiometabolic outcomes, GH-axis adaptation — are not adequately addressed by existing data, including the research record accumulated from the GHRP series since the 1990s.
Regulatory status
- US (FDA): Native ghrelin is not an approved drug and is not a scheduled controlled substance. It is not on any approved or compounded-peptide formulary. Macimorelin (Macrilen), a synthetic GHS-R1a agonist, is FDA-approved (2017) as a single-dose diagnostic for adult growth hormone deficiency — a distinct compound.
- EU / international: Native ghrelin is a research compound without established therapeutic use in any major jurisdiction. Anamorelin (Adlumiz), a synthetic GHS-R1a agonist, is approved in Japan (2020) for cancer cachexia — a distinct compound not covered here.
- WADA: GHS-R1a agonists, including ghrelin and all synthetic mimetics, are listed under the S2 class (peptide hormones, growth factors, related substances and mimetics).
Mechanism
Ghrelin is encoded by the GHRL gene and produced as a 117-amino-acid preproprotein, processed to the mature 28-residue peptide. The essential post-translational event is octanoylation of Serine-3 by GOAT (ghrelin-O-acyltransferase, MBOAT4), which requires dietary medium-chain fatty acids as acyl donors. Only the octanoylated form activates GHS-R1a with high potency. Des-acyl ghrelin — the predominant circulating form — does not bind GHS-R1a; its biology involves an as-yet-uncharacterized receptor and remains contested.
GHS-R1a is a Gq-coupled G protein-coupled receptor. Ghrelin binding activates PLC/IP3/DAG signaling, raising intracellular calcium in target cells. In anterior pituitary somatotrophs this drives GH secretion. In the hypothalamic arcuate nucleus, GHS-R1a activation on NPY/AgRP neurons overrides leptin- and insulin-mediated satiety inputs, producing the orexigenic signal. Vagal afferent fibers from the stomach also express GHS-R1a, contributing to peripheral-to-central hunger signaling. GHS-R1a additionally forms heterodimers with dopamine D1 and D2 receptors in mesolimbic circuits, providing a molecular basis for ghrelin's involvement in food reward beyond hunger. Allosteric modulation by membrane phosphoinositides and gangliosides further regulates signaling efficacy and G protein selectivity at the receptor (Damian et al., Nature Communications 2021).
LEAP2 (liver-expressed antimicrobial peptide 2), identified as a GHS-R1a inverse agonist in 2018 (Ge et al., Cell Metabolism 2018), provides a counter-regulatory signal; the LEAP2-to-ghrelin ratio may be a more informative index of receptor tone than absolute ghrelin levels alone.
Open questions
- Des-acyl ghrelin biology: Des-acyl ghrelin circulates at higher concentrations than acyl-ghrelin but does not bind GHS-R1a. Proposed functions — glucose modulation, bone effects, central actions — are investigated but biologically unresolved after more than two decades of work. The receptor mediating any independent effect has not been identified.
- Why does GHS-R1a blockade fail as an obesity treatment? Multiple ghrelin-antagonist and GOAT-inhibitor programs have underperformed clinical expectations despite the potent appetite-stimulating effect of agonists. The mechanistic asymmetry between agonism and antagonism outcomes is not well understood.
- GOAT inhibition as drug target: Blocking the acylation step that creates active ghrelin is a mechanistically attractive anti-obesity strategy. No clinically successful GOAT inhibitor has emerged from this approach.
- LEAP2-to-ghrelin ratio as therapeutic lever: Whether modulating the LEAP2-to-ghrelin ratio can produce weight-loss effects that pure ghrelin blockade has failed to deliver remains an open hypothesis (Ge et al., Cell Metabolism 2018).
- Ghrelin in food reward and addiction-adjacent behavior: GHS-R1a heterodimers with dopamine receptors are characterized at the molecular level; proposed roles in alcohol-use disorder, stress-induced eating, and mesolimbic reward processing are mechanistically plausible but have not been established in human therapeutic evidence.
- Ghrelin adaptation during extended fasting and chronic caloric restriction: Ghrelin rises acutely with caloric deprivation but shows complex adaptation over extended fasting. Whether ghrelin set-point changes contribute to weight-loss plateau or post-restriction regain is not fully characterized.
Related peptides
- GHRP-2 — synthetic hexapeptide GHS-R1a agonist; one of the first growth hormone secretagogues developed; mechanistically mimics ghrelin's pituitary GH-release effect
- GHRP-6 — synthetic hexapeptide GHS-R1a agonist; structurally distinct from ghrelin but activates the same receptor; notable for its pronounced hunger-stimulating side effect
- Ipamorelin — selective GHS-R1a agonist with minimal cortisol and prolactin co-stimulation; the most receptor-selective synthetic member of the GHRP series
- MK-677 (ibutamoren) — orally active non-peptide GHS-R1a agonist; mechanistically in the same pathway as ghrelin but engineered for oral bioavailability and extended duration
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Can the bare ghrelin peptide, without the fatty-acid tag on Ser3, still partially bind the hunger receptor?
If true, the unmodified form of ghrelin in the blood could weakly modify hunger signals. This is one possible explanation for why appetite is not a simple on/off switch, and it might suggest appetite-modulating drugs that do not need the fatty modification.
Could locking the first half of ghrelin into a rigid shape make a version that lasts longer in the body and still activates the hunger receptor?
If it worked, patients with severe muscle wasting might get a ghrelin-based drug that stays active longer. This is an engineering idea to test, not an established result, and it would still likely need the fatty tag to fully activate the receptor.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| IC50 | 0.14 nM | ChEMBL CHEMBL500468 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.673 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10760,
sequence = {GSSFLSPEHQRVQQRKESKKPPAKLQPR},
target = {ghsr},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}